Liquidia Corp — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Liquidia reported Q2 2026 net product sales of $170.4M (up 31% QoQ), net income of $74.7M, and adjusted EBITDA of $96.3M—the fourth consecutive quarter of rising profitability. As of July 31, 2026, ~5,900 unique prescriptions and 5,000+ patients started treatment since YUTREPIA launch in June 2025; >1,100 prescribers active, 30% with ≥5 referrals each. Cash increased $61.4M to $284.2M in Q2. Company is advancing 10 clinical studies for YUTREPIA and investigational L606 across PAH, PH-ILD, and new indications.
Why this rating
Transformation from loss ($41.6M Q2'25) to $74.7M net income on $170M quarterly revenue (~20% of $847M market cap) represents fundamental business inflection. Sustained 31% sequential growth, positive cash generation, and broadening pipeline pose material upside. Patent litigation risk with United Therapeutics partially offsets strength but does not negate significance.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.